• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by 4D Molecular Therapeutics Inc.

    11/14/24 4:31:18 PM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $FDMT alert in real time by email
    SC 13G/A 1 sayw24111424_13ga.htm


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND
    AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934*

    (Amendment No. 5)

    4D Molecular Therapeutics, Inc.
    (Name of Issuer)

    Common Stock, $0.0001 par value per share
    (Title of Class of Securities)

    35104E100
    (CUSIP Number)

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.


    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No. 35104E100
    13G
    Page 2 of 16 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Investors LP
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0.0%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     

    * See Item 4


    CUSIP No. 35104E100
    13G
    Page 3 of 16 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Opportunities Parent GP LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0.0%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    * See Item 4


    CUSIP No. 35104E100
    13G
    Page 4 of 16 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Opportunities GP LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0.0%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    * See Item 4


    CUSIP No. 35104E100
    13G
    Page 5 of 16 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Opportunities Portfolio GP LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0.0%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    * See Item 4


    CUSIP No. 35104E100
    13G
    Page 6 of 16 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Opportunities Illiquid Investments Sub-Master LP
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Cayman Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0.0%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     

    * See Item 4


    CUSIP No. 35104E100
    13G
    Page 7 of 16 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    O. Andreas Halvorsen
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Norway
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0.0%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     

    * See Item 4


    CUSIP No. 35104E100
    13G
    Page 8 of 16 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    David C. Ott
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0.0%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     

    * See Item 4


    CUSIP No. 35104E100
    13G
    Page 9 of 16 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Rose S. Shabet
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0*
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0*
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0*
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0.0%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     

    * See Item 4


    CUSIP No. 35104E100
    13G
    Page 10 of 16 Pages

    Item 1(a).
    Name of Issuer:

    4D Molecular Therapeutics, Inc. (the “Issuer”)

    Item 1(b).
    Address of Issuer’s Principal Executive Offices:

    5858 Horton Street #455,
    Emeryville, California 94608

    Item 2(a).
    Name of Person Filing:

    Viking Global Investors LP (“VGI”),
    Viking Global Opportunities Parent GP LLC (“Opportunities Parent”),
    Viking Global Opportunities GP LLC (“Opportunities GP”),
    Viking Global Opportunities Portfolio GP LLC (“Opportunities Portfolio GP”),
    Viking Global Opportunities Illiquid Investments Sub-Master LP (“VGOP”),
    O. Andreas Halvorsen, David C. Ott and Rose S. Shabet (collectively, the “Reporting Persons”)

    Item 2(b).
    Address of Principal Business Office or, if none, Residence:

    The business address of each of the Reporting Persons is: 600 Washington Blvd., Floor 11, Stamford, Connecticut 06901.

    Item 2(c).
    Citizenship:

    VGI is a Delaware limited partnership; Opportunities Parent, Opportunities GP and Opportunities Portfolio GP are Delaware limited liability companies; VGOP is a Cayman Islands exempted limited partnership; O. Andreas Halvorsen is a citizen of Norway; and David C. Ott and Rose S. Shabet are citizens of the United States.

    Item 2(d).
    Titles of Classes of Securities:

    Common stock, par value $0.0001 per share (“Common Stock”)

    Item 2(e).
    CUSIP NUMBER: 35104E100

    Item 3.
    If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

    (a) ☐
    Broker or dealer registered under Section 15 of the Exchange Act
       
    (b) ☐
    Bank as defined in Section 3(a)(6) of the Exchange Act
       
    (c) ☐
    Insurance company as defined in Section 3(a)(19) of the Exchange Act
       
    (d) ☐
    Investment company registered under Section 8 of the Investment Company Act of 1940
       
    (e) ☐
    Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940: see Rule 13d-1(b)(1)(ii)(E)
       
    (f) ☐
    Employee Benefit Plan, Pension Fund which is subject to the provisions of the Employee Retirement Income Security Act of 1974 or Endowment Fund; see Rule 13d-1(b)(1)(ii)(F)
       
    (g) ☐
    Parent holding company, in accordance with Rule 13d-1(b)(1)(ii)(G)


    CUSIP No. 35104E100
    13G
    Page 11 of 16 Pages
    (h) ☐
    Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act.
       
    (i) ☐
    Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940.
       
    (j) ☐
    Non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
       
    (k) ☐
    Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

    Item 4.
    Ownership:


    A. VGI

    (a) Amount beneficially owned: 0

    (b) Percent of Class: 0.0%

    (c) Number of shares as to which such person has:

    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 0
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 0

    VGI provides managerial services to VGOP. VGI has the authority to dispose of and vote the shares of Common Stock directly held by VGOP.

    Based on Rule 13d-3 of the Act, VGI may be deemed to beneficially own the shares of Common Stock directly held by VGOP. VGI does not directly own any shares of Common Stock.


    B. Opportunities Parent

    (a) Amount beneficially owned: 0

    (b) Percent of Class: 0.0%

    (c) Number of shares as to which such person has:

    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 0
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 0


    CUSIP No. 35104E100
    13G
    Page 12 of 16 Pages
    Opportunities Parent serves as the sole member of Opportunities GP, which has the authority to dispose of and vote the shares of Common Stock controlled by Opportunities Portfolio GP, which consists of the shares of Common Stock directly held by VGOP. Opportunities Parent does not directly own any shares of Common Stock.

    Based on Rule 13d-3 of the Act, Opportunities Parent may be deemed to beneficially own the shares of Common Stock directly held by VGOP.

    C. Opportunities GP

    (a) Amount beneficially owned: 0

    (b) Percent of Class: 0.0%

    (c) Number of shares as to which such person has:

    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 0
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 0

    Opportunities GP serves as the sole member of Opportunities Portfolio GP and has the authority to dispose of and vote the shares of Common Stock controlled by Opportunities Portfolio GP, which consists of the shares of Common Stock directly held by VGOP. Opportunities GP does not directly own any shares of Common Stock.

    Based on Rule 13d-3 of the Act, Opportunities GP may be deemed to beneficially own the shares of Common Stock directly held by VGOP.

    D. Opportunities Portfolio GP

    (a) Amount beneficially owned: 0

    (b) Percent of Class: 0.0%

    (c) Number of shares as to which such person has:

    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 0
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 0

    Opportunities Portfolio GP serves as the general partner of VGOP and has the authority to dispose of and vote the shares of Common Stock directly owned by VGOP. Opportunities Portfolio GP does not directly own any shares of Common Stock.

    Based on Rule 13d-3 of the Act, Opportunities Portfolio GP may be deemed to beneficially own the shares of Common Stock directly held by VGOP.

    E. VGOP

    (a) Amount beneficially owned: 0

    (b) Percent of Class: 0.0%


    CUSIP No. 35104E100
    13G
    Page 13 of 16 Pages
    (c) Number of shares as to which such person has:

    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 0
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 0

    VGOP has the authority to dispose of and vote the shares of Common Stock directly owned by it, which power may be exercised by its general partner, Opportunities Portfolio GP, and by VGI, an affiliate of Opportunities Portfolio GP, which provides managerial services to VGOP.

    Viking Global Opportunities LP (a Delaware limited partnership) and Viking Global Opportunities III LP (a Cayman Islands exempted limited partnership), through its investment in Viking Global Opportunities Intermediate LP (a Cayman Islands exempted limited partnership), invest substantially all of their assets in Viking Global Opportunities Master LP (a Cayman Islands exempted limited partnership), which in turn invests through VGOP.

    F. O. Andreas Halvorsen, David C. Ott and Rose S. Shabet

    (a) Amount beneficially owned: 0

    (b) Percent of Class: 0.0%

    (c) Number of shares as to which such person has:

    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 0
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 0

    Mr. Halvorsen, Mr. Ott and Ms. Shabet, as Executive Committee Members of Viking Global Partners LLC (general partner of VGI) and Opportunities Parent, have shared authority to dispose of and vote the shares of Common Stock beneficially owned by VGI and Opportunities Parent. None of Mr. Halvorsen, Mr. Ott and Ms. Shabet directly owns any shares of Common Stock.

    Based on Rule 13d-3 of the Act, each may be deemed to beneficially own the shares of Common Stock directly held by VGOP.


    Item 5.
    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owners of more than five percent of the class of securities, check the following ☒.

    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.

    The response to Item 4 is incorporated by reference herein.


    CUSIP No. 35104E100
    13G
    Page 14 of 16 Pages
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

    Not applicable.

    Item 8.
    Identification and Classification of Members of the Group.

    Not applicable.

    Item 9.
    Notice of Dissolution of Group.

    Not applicable.

    Item 10.
    Certification. (if filing pursuant to Rule 13d-1(c))

    By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    CUSIP No. 35104E100
    13G
    Page 15 of 16 Pages
    SIGNATURES

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

    Dated: November 14, 2024
         
           
     
    By:
    /s/ Scott M. Hendler
     
     
    Name:
    Scott M. Hendler on behalf of O. Andreas Halvorsen (1)
       
     
    By:
    /s/ Scott M. Hendler
     
     
    Name:
    Scott M. Hendler on behalf of David C. Ott (2)
       
     
    By:
    /s/ Scott M. Hendler
     
     
    Name:
    Scott M. Hendler on behalf of Rose S. Shabet (3)

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

    (1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).

    (2) Scott M. Hendler is signing on behalf of David C. Ott, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Ott on February 12, 2021 (SEC File No. 005-49737).

    (3) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Ms. Shabet on February 12, 2021 (SEC File No. 005-49737).


    CUSIP No. 35104E100
    13G
    Page 16 of 16 Pages
    EXHIBIT A - JOINT FILING AGREEMENT

    This joint filing agreement is made and entered into as of this 14th day of November, 2024, by and among Viking Global Investors LP, Viking Global Opportunities Parent GP LLC, Viking Global Opportunities GP LLC, Viking Global Opportunities Portfolio GP LLC, Viking Global Opportunities Illiquid Investments Sub-Master LP, O. Andreas Halvorsen, David C. Ott and Rose S. Shabet.

    The parties to this Agreement hereby agree to prepare jointly and file timely (and otherwise to deliver as appropriate) all filings on any Forms 3, 4, or 5 or Schedules 13D or 13G, and any and all amendments thereto and any other documents relating thereto (collectively, the “Filings”) as required to be filed pursuant to the Securities Exchange Act of 1934, as amended. The parties to this Agreement further agree and covenant that each will fully cooperate with such other parties in the preparation, timely filing, and delivery of all such Filings.

    IN WITNESS WHEREOF, the parties hereto have executed this agreement as of the date first set forth above.

    Dated: November 14, 2024
         
           
     
    By:
    /s/ Scott M. Hendler
     
     
    Name:
    Scott M. Hendler on behalf of O. Andreas Halvorsen (1)
       
     
    By:
    /s/ Scott M. Hendler
     
     
    Name:
    Scott M. Hendler on behalf of David C. Ott (2)
       
     
    By:
    /s/ Scott M. Hendler
     
     
    Name:
    Scott M. Hendler on behalf of Rose S. Shabet (3)

    (1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).

    (2) Scott M. Hendler is signing on behalf of David C. Ott, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Ott on February 12, 2021 (SEC File No. 005-49737).

    (3) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Ms. Shabet on February 12, 2021 (SEC File No. 005-49737).



    Get the next $FDMT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FDMT

    DatePrice TargetRatingAnalyst
    1/13/2025$40.00 → $15.00Outperform → Market Perform
    BMO Capital Markets
    11/21/2024$8.00Underweight
    Morgan Stanley
    9/23/2024Overweight → Neutral
    Cantor Fitzgerald
    4/15/2024$45.00Overweight
    Barclays
    4/15/2024$459.00Overweight
    Barclays
    2/7/2024$81.00Buy
    Goldman
    10/26/2023$25.00Outperform
    RBC Capital Mkts
    10/24/2023$32.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $FDMT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 4DMT Announces New Employment Inducement Grants

      EMERYVILLE, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on May 13, 2025, the compensation committee of the Company's board of directors granted eight new non-executive employees 31,800 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company's 2025 Employment Inducement Award Plan, which was approved by the Company's board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Market f

      5/16/25 4:05:00 PM ET
      $FDMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • 4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

      Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to dateInitiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) expected in Q3 2025, with topline data from both 4FRONT-1 and 4FRONT-2 expected in H2 2027RMAT designation received from FDA for 4D-150 in DME, adding to previous regulatory designations of RMAT and PRIME (EMA) for 4D-150 in wet AMD$458 million in cash, cash equivalents, and marketable securities as of March 31, 2025, expected to fund planned operations into 2028 EMERYVILLE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage

      5/8/25 4:04:02 PM ET
      $FDMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • 4DMT to Participate in Upcoming Investor Conferences

      EMERYVILLE, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in fireside chats at upcoming investor conferences in May. Members of the management team will also be available for one-on-one meetings. BofA Securities 2025 Healthcare Conference Presentation Date:Wednesday, May 14, 2025Presentation Time:2:20 p.m. PTWebcast Link:Webcast   RBC Capital Markets 2025 Global Healthcare Conference Presentatio

      5/5/25 8:00:21 AM ET
      $FDMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FDMT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by 4D Molecular Therapeutics Inc.

      SC 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)

      11/15/24 5:05:27 PM ET
      $FDMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by 4D Molecular Therapeutics Inc.

      SC 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)

      11/14/24 5:46:12 PM ET
      $FDMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by 4D Molecular Therapeutics Inc.

      SC 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)

      11/14/24 4:31:18 PM ET
      $FDMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FDMT
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by 4D Molecular Therapeutics Inc.

      SCHEDULE 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)

      5/15/25 4:29:12 PM ET
      $FDMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by 4D Molecular Therapeutics Inc.

      S-8 - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)

      5/8/25 4:33:39 PM ET
      $FDMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by 4D Molecular Therapeutics Inc.

      10-Q - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)

      5/8/25 4:21:40 PM ET
      $FDMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FDMT
    Financials

    Live finance-specific insights

    See more

    $FDMT
    Leadership Updates

    Live Leadership Updates

    See more
    • 4DMT Acquires Complement Pathway Inhibitor Payload for 4D-175 Product Candidate for Geographic Atrophy

      4DMT acquires all world-wide rights to short-form human complement factor H (sCFH) from Aevitas Therapeutics, Inc.; technology invented at University of PennsylvaniaAnnounces sCFH as payload for 4D-175 lead product candidate for geographic atrophy (GA); sCFH extensively characterized in 3 genetic mouse models and in non-human primates (NHP)CFH variants with reduced complement inhibitory function are a well-validated genetic risk factor for GA secondary to age-related macular degeneration (AMD), with approximately 75% of AMD patients carrying a high-risk variant of CFH; utilizing a precision medicine approach, this population represents a potential target population for 4D-175Continues expans

      4/24/23 8:00:00 AM ET
      $FDMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • 4D Molecular Therapeutics Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials & Development Plans for Fabry Disease Cardiomyopathy at WORLDSymposium™

      All three patients with 12 months of follow-up demonstrated improvement in multiple FDA-recommended cardiac endpoints at relatively low dose of 1E13 vg/kgCardiac biopsy demonstrated selective and widespread transgene expression within ~50% of cardiomyocytes Engaging with FDA to lift clinical hold and resume enrollment with updated exclusion criteria and highly effective rituximab/sirolimus immunosuppressive regimen to reduce risk of atypical hemolytic uremic syndrome ("aHUS")Otherwise, generally well-tolerated with no liver, heart, or dorsal root ganglia ("DRG") toxicity observedCompany to host live webcast today at 4:30 p.m. EST EMERYVILLE, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- 4D Mo

      2/22/23 4:05:00 PM ET
      $FDMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • 4D Molecular Therapeutics Announces Interim Clinical Data from On-going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD)

      Cohort 1 patients (n=5) received a single intravitreal injection of 4D-150 (3E10 vg/eye); these patients were high need patients who in the 12 months preceding trial enrollment had a mean annualized anti-VEGF injection rate of ~11Following intravitreal 4D-150, Cohort 1 patients' annualized anti-VEGF injection rate was reduced by 96.7%80% of Cohort 1 patients had not received any supplemental aflibercept injections for up to ~10 months after 4D-150 dosingCohort 1 safety and tolerability of 4D-150 demonstrated to date, with no clinically significant intraocular inflammation or hypotony reportedConference call & webcast to be held Monday November 14, 2022 at 8:00 AM E.T. EMERYVILLE, Calif.

      11/14/22 7:30:00 AM ET
      $FDMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • 4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board

      Dhaval Desai, PharmD, named as Chief Development Officer; will oversee late-stage Product Development, Medical Affairs, Scientific Communications, Regulatory and Quality operations; most recently SVP & Chief Development Officer at Iveric Bio where he led development and approval of IZERVAYChristopher Simms named as Chief Commercial Officer, effective September 25, 2024; will oversee Pre-commercial and Commercial organizations, pre-launch preparations and development; most recently SVP & Chief Commercial Officer at Iveric Bio where he led commercial strategy and execution for the launch of IZERVAYCarlos Quezada-Ruiz, M.D., FASRS, named as SVP, Therapeutic Area Head, Ophthalmology; will lead t

      8/5/24 8:00:00 AM ET
      $FDMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • 4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates

      Poised for multiple meaningful catalysts in 2024 driven by strong clinical progress across large market programs in wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and cystic fibrosis (CF)Established next-generation AAV & CRISPR/Cas-based genetic medicines partnership for central nervous system (CNS) diseases with Arbor BiotechnologiesAnnounced organizational updates, including the appointment of UCSF Professor Noriyuki Kasahara (Nori), M.D., Ph.D. as Chief Scientific OfficerWell capitalized ending 2023 with $300 million in estimated cash, financial runway guidance unchanged and cash expected to be sufficient to fund operations into H1 2026 EMERYVILLE, Calif

      1/4/24 8:00:00 AM ET
      $FDMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • 4DMT Appoints Uneek Mehra as Chief Financial and Business Officer

      EMERYVILLE, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company))), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, today announced the appointment of Uneek Mehra as Chief Financial & Business Officer of 4DMT. Mr. Mehra will succeed August J. Moretti, J.D., who is retiring, and has agreed to serve in an advisory capacity to support Mr. Mehra's transition. Mr. Mehra will lead 4DMT's finance, business development, and precommercial functions and will be a member of 4DMT's Executive Team, reporting to David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT. Mr. Mehr

      9/12/23 4:05:00 PM ET
      $FDMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FDMT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • 4D Molecular Therapeutics downgraded by BMO Capital Markets with a new price target

      BMO Capital Markets downgraded 4D Molecular Therapeutics from Outperform to Market Perform and set a new price target of $15.00 from $40.00 previously

      1/13/25 7:43:59 AM ET
      $FDMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Morgan Stanley initiated coverage on 4D Molecular Therapeutics with a new price target

      Morgan Stanley initiated coverage of 4D Molecular Therapeutics with a rating of Underweight and set a new price target of $8.00

      11/21/24 7:33:52 AM ET
      $FDMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • 4D Molecular Therapeutics downgraded by Cantor Fitzgerald

      Cantor Fitzgerald downgraded 4D Molecular Therapeutics from Overweight to Neutral

      9/23/24 7:31:34 AM ET
      $FDMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FDMT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Legal Officer Bizily Scott

      4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)

      3/10/25 8:00:20 PM ET
      $FDMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Kirn David

      4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)

      3/10/25 7:58:59 PM ET
      $FDMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Kim Robert Young

      4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)

      3/10/25 7:58:05 PM ET
      $FDMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care